cytarabine has been researched along with pyrimidine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, T; Uchida, M; Ueda, T | 1 |
| Galmarini, C; Myhren, F; Peters, G; Sandvold, ML | 1 |
| Akutsu, M; Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Koyama, D; Mori, S; Nakamura, Y; Ueda, T; Uesawa, M; Wada, T; Yamauchi, T | 1 |
3 other study(ies) available for cytarabine and pyrimidine
| Article | Year |
|---|---|
[Clinical pharmacology of anticancer agents (Part 4). Antimetabolites (1)].
Topics: Animals; Antimetabolites; Cytarabine; Fluorouracil; Leukemia, Experimental; Nucleotides; Permeability; Pyrimidines; Tumor Cells, Cultured | 1992 |
The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues.
Topics: Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; HT29 Cells; Humans; Pyrimidines | 2010 |
Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrimidines; Rituximab | 2014 |